Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors

A method of treating cancer comprising administering to a subject in need thereof a compound of formula (I):

• or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof,
• wherein:
• Q is selected from C and N;
• R1, R2, R3, and R4, which may be the same or different, are each selected from hydrogen, halogen, alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, alkynyl, —CN, —NR6R7, —OR6, —COR6, —CO2R6, —CONR6R7, —C(═NR6)NR7R8, —NR6COR7, —NR6CONR7R8, —NR6CO2R7, —SO2R6, —NR6SO2NR7R8, —NR6SO2R7, and —NR6SO2aryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, aryl, and heterocyclyl are independently optionally substituted with at least one substituent R9, or (R′ and R2), and/or (R3 and R4), together with the ring to which they are attached, form a fused ring selected from heterocyclyl and heteroaryl rings optionally substituted with at least one substituent R9;
• provided that R1 is absent when Q is N;
• R5 is selected from alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl rings, each of which is optionally substituted with at least one substituent R9;
• R6, R7 and R8, which may be the same or different, are each selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl;
• or (R6 and R7), and/or (R7 and R8) together with the atom(s) to which they are attached, each form a ring selected from heterocyclyl and heteroaryl rings optionally substituted with at least one substituent R9;
• and
• R9 is selected from halogen, haloalkyl, alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkynyl, oxo, -alkyl-NR′R″, —CN, —OR′, —NR′R″, —COR′, —CO2R′, —CONR′R″, —C(═NR′)NR″R′″, nitro, —NR′COR″, —NR′CONR′R″, —NR′CO2R″, —SO2R′, —SO2aryl, —NR′SO2NR″R′″, NR′SO2R″, and —NR′SO2aryl, wherein the cycloalkyl, aryl, heteroaryl, or heterocyclyl group are each independently optionally substituted by one, two or three substituents selected from halo, alkyl and haloalkyl, wherein R′, R″, and R′″ are independently selected from H, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, or (R′ and R″), and/or (R″ and R′″) together with the atoms to which they are attached, form a ring selected from heterocyclyl optionally substituted by halogen and alkyl, and heteroaryl rings optionally substituted by halogen and alkyl;
• wherein the cancer has a mutated B-Raf gene or a mutated Ras gene.